Skeletal Muscle Mass Change During Chemotherapy: A Systematic Review and Meta-analysis

Skeletal muscle mass loss is an emerging concern in oncology. Our systematic review and meta-analysis identified the mean difference in skeletal muscle index pre- to post-chemotherapy and synthesized potential key factors. We searched primary original research published through October 2019 in four...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 40; no. 5; pp. 2409 - 2418
Main Authors JANG, MIN KYEONG, PARK, CHANG, HONG, SUSAN, LI, HONGJIN, RHEE, ESTHER, DOORENBOS, ARDITH Z.
Format Journal Article
LanguageEnglish
Published Greece International Institute of Anticancer Research 01.05.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Skeletal muscle mass loss is an emerging concern in oncology. Our systematic review and meta-analysis identified the mean difference in skeletal muscle index pre- to post-chemotherapy and synthesized potential key factors. We searched primary original research published through October 2019 in four databases: MEDLINE via PubMed, Scopus, CINAHL, and Embase. Fifteen studies were included, 60% published in the past 2 years (2018-2019). Advanced non-small cell lung cancer was the most frequently reported cancer, and overall survival the most often identified key related factor. Mean difference in skeletal muscle index during chemotherapy was 2.72 (95%CI=1.77-3.67, p=0.00), with muscle loss in males (4.52, 95%CI=3.34-5.71, p=0.00) about 1.6 times higher than that in females (2.86, 95%CI=0.81-4.92, p=0.01). Oncologists should recognize sex-specific differences in skeletal muscle mass loss during chemotherapy and consider adjusting treatment accordingly.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
ISSN:0250-7005
1791-7530
1791-7530
DOI:10.21873/anticanres.14210